Sandoz
Novartis expands Pear partnership to tackle opioid and substance use disorder
April 23, 2018Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder
Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …
Novartis steps into the medical marijuana business
March 20, 2018Manufacturing and Production, Sales and Marketing Medical marijuana, Novartis, Sandoz, biotech, drugs, pharma, pharmaceutical
Canada’s burgeoning medical marijuana industry has finally drawn in a big pharma player. Tilray, a producer of medical cannabis products, …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
FDA accepts license application for Novartis’ rituximab biosimilar
September 12, 2017Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab
Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …
UK launch of two Novartis biosimilars could cut NHS costs
June 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab
Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …
Mounting US pricing pressures cutting into quarterly sales, Novartis admits
May 31, 2017Research and Development, Sales and Marketing Novartis, Sandoz
Novartis has revealed that increasing pressure on pricing in the US has impacted its second-quarter business, cutting into sales generated …
EMA recommends suspension of 331 drugs over testing concerns
March 28, 2017Manufacturing and Production, Sales and Marketing Aurobindo, Micro Therapeutic Research Labs, Novartis, Sandoz
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has called for the suspension of 331 drugs due to …
FDA approves Novartis Enbrel biosimilar
August 31, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli
Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …
FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote
July 14, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …
New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile
July 7, 2016Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars
Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …
Novartis aims to launch five major global biosimilars by 2020
June 21, 2016Manufacturing and Production, Research and Development 2020, Novartis, Sandoz, biosimilars
Novartis (VTX: NOVN) has announced plans to triple its biosimilar portfolio by 2020, with the launch of five major biosimilar …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
Sandoz biosimilar accepted for regulatory submission by EMA
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application for …
Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar
April 8, 2016Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval
Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
